0001326190 false 0001326190 2021-09-23 2021-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): September 23, 2021





(Exact name of registrant as specified in its charter)




Delaware   001-32587   20-2726770

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


910 Clopper Road, Suite 201S

Gaithersburg, Maryland

(Address of principal executive offices)       (Zip Code)


Registrant’s telephone number including area code: (240) 654-1450


(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.0001 per share ALT The NASDAQ Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨







Item 5.07 Submission of Matters to a Vote of Security Holders.


On September 23, 2021, Altimmune, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). As of August 10, 2021, the record date for the 2021 Annual Meeting, there were 39,705,884 shares of the Company’s common stock outstanding and entitled to vote at the 2021 Annual Meeting. A total of 28,489,957 shares of common stock were present or represented by proxy at the 2021 Annual Meeting, representing 71.75% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:


Proposal No. 1: Election of Directors. The results were as follows:


Director  For   Withhold   Broker
Mitchel Sayare, Ph.D.   18,420,433    392,066    9,677,458 
Vipin K. Garg, Ph.D.   18,417,793    394,706    9,677,458 
David J. Drutz, M.D.   15,118,630    3,693,869    9,677,458 
John M. Gill   11,033,020    7,779,479    9,677,458 
Philip L. Hodges   18,400,560    411,939    9,677,458 
Diane Jorkasky, M.D.   18,406,747    405,752    9,677,458 
Wayne Pisano   14,848,010    3,964,489    9,677,458 
Klaus O. Schafer, M.D., MPH   18,400,808    411,691    9,677,458 


Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021. The results were as follows:


For   Against   Abstain 
 28,430,498    29,266    30,193 


Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:


For   Against   Abstain   Broker Non-Votes 
 8,321,213    10,439,681    51,605    9,677,458 


Proposal No. 4: Vote to authorize the adjournment of the 2021 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:


For   Against   Abstain 
 18,509,254    9,785,811    194,892 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: September 24, 2021



/s/ William Brown

    Name: William Brown
    Title: Chief Financial Officer